Could a weekly shot transform life with type 1 diabetes?
NCT ID NCT06630585
Summary
This study is testing whether adding a once-weekly medication called tirzepatide to standard insulin pump therapy helps adults with type 1 diabetes achieve better blood sugar control. Researchers will compare two groups over 12 weeks: one receiving the new drug plus their usual insulin, and another continuing with insulin alone. The goal is to see if this combination keeps blood sugar in a healthy range more often while potentially reducing insulin needs and body weight.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES (T1D) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
DiaCenTRE - Hirslanden Clinique des Grangettes
RECRUITINGChêne-Bougeries, Canton of Geneva, 1224, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kantonsspital Olten
RECRUITINGOlten, Canton of Solothurn, 4600, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Luzerner Kantonspital
RECRUITINGLucerne, 6000, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.